GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » EV-to-EBIT

Elicera Therapeutics AB (OSTO:ELIC) EV-to-EBIT : -0.26 (As of May. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Elicera Therapeutics AB's Enterprise Value is kr4.17 Mil. Elicera Therapeutics AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was kr-16.32 Mil. Therefore, Elicera Therapeutics AB's EV-to-EBIT for today is -0.26.

The historical rank and industry rank for Elicera Therapeutics AB's EV-to-EBIT or its related term are showing as below:

OSTO:ELIC' s EV-to-EBIT Range Over the Past 10 Years
Min: -62.63   Med: 0   Max: 0
Current: -0.26

OSTO:ELIC's EV-to-EBIT is ranked worse than
100% of 422 companies
in the Biotechnology industry
Industry Median: 10.345 vs OSTO:ELIC: -0.26

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Elicera Therapeutics AB's Enterprise Value for the quarter that ended in Dec. 2023 was kr60.82 Mil. Elicera Therapeutics AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was kr-16.32 Mil. Elicera Therapeutics AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -26.84%.


Elicera Therapeutics AB EV-to-EBIT Historical Data

The historical data trend for Elicera Therapeutics AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicera Therapeutics AB EV-to-EBIT Chart

Elicera Therapeutics AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -3.58 -1.33 -3.73

Elicera Therapeutics AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.33 -1.78 -0.93 -2.02 -3.73

Competitive Comparison of Elicera Therapeutics AB's EV-to-EBIT

For the Biotechnology subindustry, Elicera Therapeutics AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elicera Therapeutics AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicera Therapeutics AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Elicera Therapeutics AB's EV-to-EBIT falls into.



Elicera Therapeutics AB EV-to-EBIT Calculation

Elicera Therapeutics AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=4.166/-16.322
=-0.26

Elicera Therapeutics AB's current Enterprise Value is kr4.17 Mil.
Elicera Therapeutics AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-16.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elicera Therapeutics AB  (OSTO:ELIC) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Elicera Therapeutics AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-16.322/60.82292
=-26.84 %

Elicera Therapeutics AB's Enterprise Value for the quarter that ended in Dec. 2023 was kr60.82 Mil.
Elicera Therapeutics AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-16.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elicera Therapeutics AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Elicera Therapeutics AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Elicera Therapeutics AB (OSTO:ELIC) Business Description

Traded in Other Exchanges
Address
Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

Elicera Therapeutics AB (OSTO:ELIC) Headlines

No Headlines